Beth H Shaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3482471/publications.pdf Version: 2024-02-01



ΒΕΤΗ Η SHA7

#	Article	IF	CITATIONS
1	COVID-19 convalescent plasma. Blood, 2022, 140, 196-207.	0.6	31
2	Blood donor eligibility criteria for medical conditions: A <scp>BEST</scp> collaborative study. Vox Sanguinis, 2022, 117, 929-936.	0.7	5
3	Evaluation of amotosalen and <scp>UVA pathogen</scp> â€reduced apheresis platelets after 7â€day storage. Transfusion, 2022, 62, 1619-1629.	0.8	3
4	Transfusion reactions associated with <scp>COVID</scp> â€19 convalescent plasma therapy for <scp>SARSâ€CoV</scp> â€2. Transfusion, 2021, 61, 78-93.	0.8	17
5	Frequency of rare, serious donor reactions: International perspective. Transfusion, 2021, 61, 1780-1788.	0.8	6
6	Commentary: Patient blood management in the era of coronavirus disease 2019—is anything really different?. JTCVS Open, 2021, 5, 97-98.	0.2	0
7	<scp>COVID</scp> â€19 convalescent plasma: Interim recommendations from the <scp>AABB</scp> . Transfusion, 2021, 61, 1313-1323.	0.8	40
8	Screening of blood donors for sickle cell trait using a DNA â€based approach: Frequency in a multiethnic donor population. Transfusion, 2021, 61, 2008-2013.	0.8	5
9	Results from the blood donor competence, autonomy, and relatedness enhancement (blood donor) Tj ETQq1 1	0.784314	rgBT /Overloc
10	A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	3.9	131
11	Blood transfusions in gunshotâ€woundâ€related emergency department visits and hospitalizations in the United States. Transfusion, 2021, 61, 2277-2289.	0.8	3
12	Fear is associated with attrition of firstâ€ŧime whole blood donors: A longitudinal examination of donor confidence and attitude as potential mediators. Transfusion, 2021, 61, 3372-3380.	0.8	5
13	Promoting awareness of donationâ€related iron depletion among high risk blood donors. Transfusion, 2021, 61, 3353-3360.	0.8	4
14	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	3.9	43
15	The impact of age and sex on firstâ€ŧime donor return behavior. Transfusion, 2020, 60, 84-93.	0.8	14
16	Remunerating donors to ensure a safe and available blood supply. Transfusion, 2020, 60, S134-S137.	0.8	5
17	Examination of the relationship between iron status and cognitive function among healthy young women with and without a recent history of blood donation. Transfusion, 2020, 60, 2886-2895.	0.8	4
18	Earlier the better: convalescent plasma. Blood, 2020, 136, 652-654.	0.6	21

#	Article	IF	CITATIONS
19	Comparative changes of preâ€operative autologous transfusions and periâ€operative cell salvage in the United States. Transfusion, 2020, 60, 2260-2271.	0.8	3
20	Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: Application of a statistically representative sampling methodology to assess risk in US blood centers. Transfusion, 2020, 60, 1987-1997.	0.8	4
21	Catch those antibodies before they fall. Blood, 2020, 136, 2489-2490.	0.6	1
22	Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 499.	0.7	38
23	Zika virus and its implications on cord blood banking and transplantation. Transfusion, 2020, 60, 889-891.	0.8	2
24	A randomized controlled trial of a tabletâ€based intervention to address predonation fears among high school donors. Transfusion, 2020, 60, 1450-1453.	0.8	9
25	Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors. Vox Sanguinis, 2020, 115, 703-711.	0.7	9
26	Perioperative Transfusions and Venous Thromboembolism. Pediatrics, 2020, 145, .	1.0	16
27	Warming Up to Cold-stored Platelets. Anesthesiology, 2020, 133, 1161-1163.	1.3	3
28	How did we rapidly implement a convalescent plasma program?. Transfusion, 2020, 60, 1348-1355.	0.8	40
29	Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion. Journal of Clinical Investigation, 2020, 130, 2270-2285.	3.9	69
30	Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020, 130, 2757-2765.	3.9	649
31	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. Vox Sanguinis, 2019, 114, 783-794.	0.7	14
32	Seasonal variability is not observed in the rates of high antiâ€A and antiâ€B titers in plasma, apheresis platelet, and whole blood units tested by different methods. Transfusion, 2019, 59, 762-767.	0.8	16
33	An automated motivational interview promotes donation intention and selfâ€efficacy among experienced whole blood donors. Transfusion, 2019, 59, 2876-2884.	0.8	9
34	Red blood cells: beyond the transfusion. Blood, 2019, 133, 2627-2628.	0.6	2
35	Sociodemographic and behavioral characteristics associated with blood donation in the United States: a populationâ€based study. Transfusion, 2019, 59, 2899-2907.	0.8	37
36	Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion, 2019, 59, 2733-2748.	0.8	1

#	Article	IF	CITATIONS
37	Ten years of TRALI mitigation: measuring our progress. Transfusion, 2019, 59, 2567-2574.	0.8	25
38	Reexamination of the chromiumâ€51–labeled posttransfusion red blood cell recovery method. Transfusion, 2019, 59, 2264-2275.	0.8	21
39	Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood, 2019, 133, 1831-1839.	0.6	100
40	Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. Frontiers in Microbiology, 2019, 10, 29.	1.5	14
41	Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. Transfusion, 2019, 59, 1723-1733.	0.8	25
42	Donor incentives improve cardiovascular disease risk profile and donation rates. Transfusion, 2019, 59, 250-258.	0.8	0
43	Factors associated with red blood cell, platelet, and plasma transfusions among inpatient hospitalizations: a nationally representative study in the United States. Transfusion, 2019, 59, 500-507.	0.8	14
44	Donor Iron Deficiency Study (DIDS): protocol of a study to test whether iron deficiency in blood donors affects red blood cell recovery after transfusion. Blood Transfusion, 2019, 17, 274-280.	0.3	6
45	Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee. Transfusion, 2018, 58, 1065-1075.	0.8	2
46	Transfusionâ€ŧransmitted and communityâ€acquired babesiosis in New York, 2004 to 2015. Transfusion, 2018, 58, 660-668.	0.8	37
47	Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging. Aging, 2018, 10, 3017-3041.	1.4	16
48	Riskâ€based decision making: a good start to aiding US blood policy decisions?. Transfusion, 2018, 58, 1827-1830.	0.8	5
49	Transfusion of Plasma and Plasma Derivatives. , 2018, , 1744-1758.		1
50	Human Blood Group Antigens and Antibodies. , 2018, , 1687-1701.		0
51	Apheresis to Mitigate Atherosclerotic Vascular Disease. American Journal of Hypertension, 2018, 31, 945-949.	1.0	4
52	Infectious Complications of Blood Transfusion. , 2018, , 241-266.		0
53	Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry. JAMA Surgery, 2018, 153, 826.	2.2	133
54	The Development of a Social Networking–Based Relatedness Intervention Among Young, First-Time Blood Donors: Pilot Study. JMIR Public Health and Surveillance, 2018, 4, e44.	1.2	4

#	Article	IF	CITATIONS
55	Low Dose Umbilical Cord Blood Transplant Results in Skewed Immune Cell Composition Which May Impact Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 5672-5672.	0.6	0
56	Applying self-determination theory to the blood donation context: The blood donor competence, autonomy, and relatedness enhancement (Blood Donor CARE) trial. Contemporary Clinical Trials, 2017, 53, 44-51.	0.8	19
57	First cases of Zika virus–infected US blood donors outside states with areas of active transmission. Transfusion, 2017, 57, 770-778.	0.8	59
58	Impact of predictive scoring model and eâ€mail messages on African American blood donors. Transfusion, 2017, 57, 1515-1521.	0.8	6
59	Trends in <scp>US</scp> minority red blood cell unit donations. Transfusion, 2017, 57, 1226-1234.	0.8	34
60	Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation. Archives of Pathology and Laboratory Medicine, 2017, 141, 1705-1711.	1.2	16
61	How do we manage blood donors and recipients after a positive Zika screening result?. Transfusion, 2017, 57, 2077-2083.	0.8	9
62	A motivational interview promotes retention of blood donors with high internal motivation. Transfusion, 2017, 57, 2433-2439.	0.8	11
63	Trends in age and red blood cell donation habits among several racial/ethnic minority groups in the United States. Transfusion, 2017, 57, 1644-1655.	0.8	25
64	Impact of Uniform Methods on Interlaboratory Antibody Titration Variability: Antibody Titration and Uniform Methods. Archives of Pathology and Laboratory Medicine, 2017, 141, 131-138.	1.2	34
65	Zika Virus and the Blood Supply: What Do We Know?. Transfusion Medicine Reviews, 2017, 31, 1-10.	0.9	42
66	Immune regulation of sickle cell alloimmunization. ISBT Science Series, 2017, 12, 248-253.	1.1	10
67	Recent viral infection in US blood donors and health-related quality of life (HRQOL). Quality of Life Research, 2017, 26, 349-357.	1.5	19
68	Implications of the US Food and Drug Administration draft guidance for mitigating septic reactions from platelet transfusions. Blood Advances, 2017, 1, 1142-1147.	2.5	10
69	Correlation of West Nile Virus Incidence in Donated Blood with West Nile Neuroinvasive Disease Rates, United States, 2010–2012. Emerging Infectious Diseases, 2017, 23, 212-219.	2.0	16
70	Changes in blood center red blood cell distributions in the era of patient blood management: the trends for collection (TFC) study. Transfusion, 2016, 56, 1965-1973.	0.8	51
71	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis, 2016, 31, 149-338.	0.7	384
72	Evidence of relative iron deficiency in platelet―and plasmaâ€pheresis donors correlates with donation frequency. Journal of Clinical Apheresis, 2016, 31, 551-558.	0.7	15

#	Article	IF	CITATIONS
73	A brief motivational interview with action and coping planning components enhances motivational autonomy among volunteer blood donors. Transfusion, 2016, 56, 1636-1644.	0.8	25
74	Emerging Infections and Blood Safety in the 21st Century. Annals of Internal Medicine, 2016, 165, 57.	2.0	10
75	Motivations for donating and attitudes toward screening policies in US blood donors with viral infection. Transfusion, 2016, 56, 2013-2020.	0.8	19
76	Perception of low-titer group A plasma and potential barriers to using this product: A blood center's experience serving community and academic hospitals. Transfusion and Apheresis Science, 2016, 55, 141-145.	0.5	10
77	Survey of Irradiation Practice for the Prevention of Transfusion-Associated Graft-versus-Host Disease. Archives of Pathology and Laboratory Medicine, 2016, 140, 1092-1097.	1.2	31
78	ä,ʿ床实践ä,治痗性å•采æœ⁻应用指å⊷——基于美å᠈½è¡€æµ†ç½®æ¢å¦ä¼šç¼–写委å~ã	i¼ šç\$ "å¾	^ª è ¯&2ţ•¥ï¹⁄ 4šç
79	Prolonged red cell storage before transfusion increases extravascular hemolysis. Journal of Clinical Investigation, 2016, 127, 375-382.	3.9	166
80	Detection of bacterial contamination in apheresis platelets: is apheresis technology a factor?. Transfusion, 2015, 55, 2113-2122.	0.8	12
81	Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion, 2015, 55, 1098-1107.	0.8	49
82	Acceptability and Feasibility of a Culturally Tailored Internet-Delivered Intervention to Promote Blood Donation in Blacks. Health Promotion Practice, 2015, 16, 227-235.	0.9	11
83	Virome Analysis of Transfusion Recipients Reveals a Novel Human Virus That Shares Genomic Features with Hepaciviruses and Pegiviruses. MBio, 2015, 6, e01466-15.	1.8	80
84	American Society for Apheresis Guidelines Support Use of Red Cell Exchange Transfusion for Severe Malaria With High Parasitemia. Clinical Infectious Diseases, 2014, 58, 302-303.	2.9	10
85	Policies and Procedures Related to Testing for Weak D Phenotypes and Administration of Rh Immune Clobulin: Results and Recommendations Related to Supplemental Questions in the Comprehensive Transfusion Medicine Survey of the College of American Pathologists. Archives of Pathology and Laboratory Medicine. 2014, 138, 620-625.	1.2	35
86	Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. Blood, 2014, 124, 1868-1872.	0.6	22
87	How we developed and use the <scp>A</scp> merican <scp>S</scp> ociety for <scp>A</scp> pheresis guidelines for therapeutic apheresis procedures. Transfusion, 2014, 54, 17-25.	0.8	10
88	Current patterns of use in therapeutic apheresis: a metropolitan center experience. Transfusion, 2014, 54, 1899-1900.	0.8	1
89	Development of common metrics for donation attitude, subjective norm, perceived behavioral control, and intention for the blood donation context. Transfusion, 2014, 54, 839-847.	0.8	51
90	The value of areaâ€based analyses of donation patterns for recruitment strategies. Transfusion, 2014, 54, 3051-3060.	0.8	12

#	Article	IF	CITATIONS
91	Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15798-15803.	3.3	203
92	A comparison of adverse reaction rates for <scp>PAS C</scp> versus plasma platelet units. Transfusion, 2014, 54, 1927-1934.	0.8	86
93	Red Blood Cell Alloimmunization Mitigation Strategies. Transfusion Medicine Reviews, 2014, 28, 137-144.	0.9	53
94	Early trauma induced coagulopathy (ETIC): Prevalence across the injury spectrum. Injury, 2014, 45, 910-915.	0.7	40
95	The Blood Donor Identity Survey: a multidimensional measure of blood donor motivations. Transfusion, 2014, 54, 2098-2105.	0.8	38
96	Bye-bye TRALI: by understanding and innovation. Blood, 2014, 123, 3374-3376.	0.6	10
97	Evaluating a program to increase blood donation among racial and ethnic minority communities in <scp>N</scp> ew <scp>Y</scp> ork <scp>C</scp> ity. Transfusion, 2014, 54, 3061-3067.	0.8	34
98	Lewis, I, P1PK and GLOB Blood Group Systems. , 2013, , 171-176.		0
99	ABO and H Blood Group System. , 2013, , 149-156.		2
100	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue. Journal of Clinical Apheresis, 2013, 28, 145-284.	0.7	520
101	Cryoprecipitate and Fibrinogen Concentrates. , 2013, , 227-230.		2
102	Measuring the processes of change for increasing blood donation in black adults. Transfusion, 2013, 53, 1280-1290.	0.8	19
103	Blood donations motivators and barriers: A descriptive study of African American and white voters. Transfusion and Apheresis Science, 2013, 48, 87-93.	0.5	29
104	The integration of high-throughput testing of blood donors for cardiovascular disease risk assessment and prevention. Transfusion and Apheresis Science, 2013, 49, 263-267.	0.5	4
105	Iron Overload. , 2013, , 449-451.		0
106	The impact of a massive transfusion protocol (1:1:1) on major hepatic injuries: Does it increase abdominal wall closure rates?. Canadian Journal of Surgery, 2013, 56, E128-E134.	0.5	27
107	Massive transfusion. Current Opinion in Hematology, 2013, 20, 521-525.	1.2	13
108	Patient Blood Management. JAMA Surgery, 2013, 148, 491.	2.2	4

#	Article	IF	CITATIONS
109	Kell and Kidd Blood Group Systems. , 2013, , 163-166.		Ο
110	Adverse Donor Reactions. , 2013, , 53-59.		2
111	Rh and RhAG Blood Group Systems. , 2013, , 157-162.		1
112	Overview of Infectious Disease Testing. , 2013, , 73-78.		1
113	Other Blood Group Systems, Collections, and Series. , 2013, , 177-183.		Ο
114	Human Immunoglobulin Preparations. , 2013, , 243-254.		0
115	Rh Immune Globulin. , 2013, , 255-258.		0
116	MNS and Duffy Blood Group Systems. , 2013, , 167-170.		0
117	Massive Transfusion. , 2013, , 367-372.		1
118	Serologic Testing of Donor Products. , 2013, , 69-72.		0
119	Perinatal Transfusion Medicine. , 2013, , 307-315.		5
120	Bacterial Detection Methods. , 2013, , 103-107.		1
121	Transfusion Practices and Infections At Four Level III Neonatal Intensive Care Units. Blood, 2013, 122, 3657-3657.	0.6	1
122	Role of the Transfusion Service Physician. , 2013, , 109-115.		0
123	Metabolic, Hypotensive and Other Acute Reactions and Complications. , 2013, , 427-431.		Ο
124	Role of the Physician in the Blood Center. , 2013, , 31-35.		0
125	Therapeutic Phlebotomy. , 2013, , 529-531.		0
126	Evidence Of Relative Iron Deficiency in Apheresis Platelet Donors Correlates With Donation Frequency. Blood, 2013, 122, 1155-1155.	0.6	1

#	Article	IF	CITATIONS
127	Base deficit as a marker of survival after traumatic injury. Journal of Trauma, 2012, 72, 844-851.	2.3	38
128	Giving TRALI the one-two punch. Blood, 2012, 119, 1620-1621.	0.6	5
129	Outcomes after Massive Transfusion in Nontrauma Patients in the Era of Damage Control Resuscitation. American Surgeon, 2012, 78, 679-684.	0.4	41
130	Demographic differences in estimated blood donor eligibility prevalence in the United States. Transfusion, 2012, 52, 1050-1061.	0.8	24
131	Cardiovascular disease risk assessment and prevention in blood donors. Transfusion, 2012, 52, 2174-2182.	0.8	8
132	West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. Transfusion, 2012, 52, 2664-2670.	0.8	11
133	Evaluating the Role of Blood Collection Centers in Public Health: A Status Report. Transfusion Medicine Reviews, 2012, 26, 58-67.	0.9	8
134	Determination of human platelet antigen typing by molecular methods: Importance in diagnosis and early treatment of neonatal alloimmune thrombocytopenia. American Journal of Hematology, 2012, 87, 525-528.	2.0	24
135	Donor Availability for Extended Phenotype Matching for Transfusion in Thalassemia and Sickle Cell Disease Blood, 2012, 120, 2287-2287.	0.6	1
136	Effects of Pooling Multiple Red Blood Cell Units to Improve Storage. Blood, 2012, 120, 3437-3437.	0.6	0
137	Outcomes after massive transfusion in nontrauma patients in the era of damage control resuscitation. American Surgeon, 2012, 78, 679-84.	0.4	16
138	<i>The Effects of Protocolized Use of Recombinant Factor VIIa Within a Massive Transfusion Protocol in a Civilian Level I Trauma Center</i> . American Surgeon, 2011, 77, 1043-1049.	0.4	20
139	Pathophysiology of Early Trauma-Induced Coagulopathy: Emerging Evidence for Hemodilution and Coagulation Factor Depletion. Journal of Trauma, 2011, 70, 1401-1407.	2.3	90
140	Demographic Patterns of Blood Donors and Donations in a Large Metropolitan Area. Journal of the National Medical Association, 2011, 103, 351-357.	0.6	52
141	Transfusion-related acute lung injury: from bedside to bench and back. Blood, 2011, 117, 1463-1471.	0.6	113
142	Contribution of attitudinal factors to blood donation in African American church attendees. Transfusion, 2011, 51, 158-165.	0.8	23
143	Residual risk of D alloimmunization: is it time to feel safe about platelets from D+ donors?. Transfusion, 2011, 51, 1132-1135.	0.8	17
144	Uncrossmatched blood transfusions for trauma patients in the emergency department: incidence, outcomes and recommendations. Canadian Journal of Surgery, 2011, 54, 111-115.	0.5	29

#	Article	IF	CITATIONS
145	The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center. American Surgeon, 2011, 77, 1043-9.	0.4	16
146	Minority donation in the United States: challenges and needs. Current Opinion in Hematology, 2010, 17, 544-549.	1.2	56
147	Early Predictors of Massive Transfusion in Patients Sustaining Torso Gunshot Wounds in a Civilian Level I Trauma Center. Journal of Trauma, 2010, 68, 298-304.	2.3	42
148	Guidelines on the use of therapeutic apheresis in clinical practice—Evidenceâ€based approach from the apheresis applications committee of the American Society for Apheresis. Journal of Clinical Apheresis, 2010, 25, 83-177.	0.7	441
149	Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion, 2010, 50, 493-500.	0.8	216
150	Transfusion medicine as a profession: evolution over the past 50 years. Transfusion, 2010, 50, 2536-2541.	0.8	13
151	Therapeutic Thrombocytapheresis. , 2009, , 403.		1
152	Bacterial Detection Methods. , 2009, , 83-86.		1
153	Transfusion Transmitted Diseases. , 2009, , 361-371.		8
154	Lewis, I and P Blood Group Systems. , 2009, , 139-144.		0
155	Albumin and Related Products. , 2009, , 185-191.		0
156	Antibody Identification. , 2009, , 103-110.		0
157	Pretransfusion Testing. , 2009, , 93-101.		1
158	LDL Pheresis. , 2009, , 411.		0
159	MNS and Duffy Blood Group Systems. , 2009, , 133-137.		1
160	Transfusion Associated Graft Versus Host Disease. , 2009, , 345-352.		0
161	Human Immunoglobulin Preparations. , 2009, , 193-203.		0
162	Direct Antiglobulin Test. , 2009, , 111-114.		0

#	Article	IF	CITATIONS
163	Kell and Kidd Blood Group Systems. , 2009, , 129-132.		Ο
164	Other Blood Group Systems, Collections and Antigens. , 2009, , 145-149.		0
165	Therapeutic Plasma Exchange. , 2009, , 383-397.		1
166	Autoimmune Hemolytic Anemias. , 2009, , 251-258.		1
167	Therapeutic Leukapheresis. , 2009, , 405-406.		1
168	Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. Journal of Clinical Apheresis, 2009, 24, 115-119.	0.7	25
169	Critical evaluation of informed consent forms for adult and minor aged whole blood donation used by United States blood centers. Transfusion, 2009, 49, 1136-1145.	0.8	15
170	Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization?. Transfusion, 2009, 49, 1070-1075.	0.8	60
171	A novel mouse model of red blood cell storage and posttransfusion in vivo survival. Transfusion, 2009, 49, 1546-1553.	0.8	106
172	Minority and foreignâ€born representation among US blood donors: demographics and donation frequency for 2006. Transfusion, 2009, 49, 2221-2228.	0.8	53
173	Motivators and barriers to blood donation in African American college students. Transfusion and Apheresis Science, 2009, 41, 191-197.	0.5	48
174	Transfusion Management of Trauma Patients. Anesthesia and Analgesia, 2009, 108, 1760-1768.	1.1	160
175	Rh Blood Group System. , 2009, , 123-127.		0
176	Improvements in Early Mortality and Coagulopathy are Sustained Better in Patients With Blunt Trauma After Institution of a Massive Transfusion Protocol in a Civilian Level I Trauma Center. Journal of Trauma, 2009, 66, 1616-1624.	2.3	252
177	The Role of the Transfusion Service Physician. , 2009, , 87-92.		1
178	Cryoprecipitate. , 2009, , 175-178.		1
179	Frozen Blood Products. , 2009, , 223-225.		1
180	Allergic, Anaphylactoid and Anaphylactic Reactions. , 2009, , 311-315.		1

#	Article	IF	CITATIONS
181	Racial Differences in Motivators and Barriers to Blood Donation Among Blood Donors. Archives of Pathology and Laboratory Medicine, 2009, 133, 1444-1447.	1.2	46
182	Platelet Products. , 2009, , 167-174.		0
183	Microchimerism. , 2009, , 353-355.		0
184	Irradiation of Blood Products. , 2009, , 209-214.		0
185	Washed Blood Products. , 2009, , 227-229.		0
186	Transfusion Management in Patients with Hemoglobinopathies. , 2009, , 259-267.		0
187	ABO and H Blood Group Systems. , 2009, , 115-122.		0
188	Perioperative Blood Management. , 2009, , 293-301.		0
189	Immunoadsorption. , 2009, , 413-414.		0
190	Therapeutic Erythrocytapheresis. , 2009, , 399-401.		0
191	Rh Immune Globulin. , 2009, , 205-208.		0
192	Perinatal Transfusion Medicine. , 2009, , 241-249.		1
193	Metabolic, Hypotensive and Other Acute Reactions and Complications. , 2009, , 339-342.		0
194	Therapeutic Phlebotomy. , 2009, , 415-416.		0
195	Massive Transfusion. , 2009, , 287-291.		0
196	Overview of Therapeutic Apheresis. , 2009, , 373-382.		0
197	Utility of consecutive repeat HIT ELISA testing for heparinâ€induced thrombocytopenia. American Journal of Hematology, 2008, 83, 212-217.	2.0	24
198	Integrating Molecular Technologies for Red Blood Cell Typing and Compatibility Testing Into Blood Centers and Transfusion Services. Transfusion Medicine Reviews, 2008, 22, 117-132.	0.9	114

#	Article	IF	CITATIONS
199	Blood Donation and Blood Transfusion: Special Considerations for African Americans. Transfusion Medicine Reviews, 2008, 22, 202-214.	0.9	61
200	Blood Management: Conservation, Salvage, and Alternatives to Allogeneic Transfusion. , 2007, , 419-434.		0
201	Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American society for apheresis. Journal of Clinical Apheresis, 2007, 22, 106-175.	0.7	308
202	Category IV indications for therapeutic apheresis—ASFA fourth special issue. Journal of Clinical Apheresis, 2007, 22, 176-180.	0.7	26
203	The new approach to assignment of ASFA categories—Introduction to the fourth special issue: Clinical applications of therapeutic apheresis. Journal of Clinical Apheresis, 2007, 22, 96-105.	0.7	65
204	How we approach an apheresis request for a Category III, Category IV, or noncategorized indication. Transfusion, 2007, 47, 1963-1971.	0.8	13
205	A Pilot Trial To Assess College Student's Willingness To Donate Blood Blood, 2007, 110, 4029-4029.	0.6	1
206	Sequential clinical and histopathological changes in collagenous and lymphocytic colitis over time. Modern Pathology, 2004, 17, 395-401.	2.9	30
207	The Use of Platelet Antibody Testing at a Tertiary Medical Center Blood, 2004, 104, 3631-3631.	0.6	8
208	Prevalence and Significance of Inflammatory Bowel Disease-Like Morphologic Features in Collagenous and Lymphocytic Colitis. American Journal of Surgical Pathology, 2002, 26, 1414-1423.	2.1	142
209	The Terminal Ileum Is Affected in Patients With Lymphocytic or Collagenous Colitis. American Journal of Surgical Pathology, 2002, 26, 1484-1492.	2.1	97
210	Livers from Patients with Apolipoprotein A-I Amyloidosis Are Not Suitable as "Domino―Donors. Modern Pathology, 2001, 14, 577-580.	2.9	18
211	Blood transfusion: preoperative considerations and complications. , 0, , 252-264.		0
212	Transfusion-Associated Graft-Versus-Host Disease and Microchimerism. , 0, , 107-116.		1